Search

Your search keyword '"Bouabdallah, K."' showing total 211 results
Start Over Author "Bouabdallah, K." Publication Year Range Last 10 years
211 results on '"Bouabdallah, K."'

4. Long‐term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in elderly mantle cell lymphoma patients. For the LYSA group.

Author

Carras, S., primary, Torroja, A., additional, Emadali, A., additional, Daguindau, N., additional, Tempescul, A., additional, Macro, M., additional, Moreau, A., additional, Tchernonog, E., additional, Houot, R., additional, Schmitt, A., additional, Dartigeas, C., additional, Dupuis, J., additional, Jardin, F., additional, Banos, A., additional, Corm, S., additional, Barbieux, S., additional, Zerazhi, H., additional, Arkam, Y., additional, Fouillet, L., additional, Fontan, J., additional, Vilque, J., additional, Moles, M., additional, Sarkozy, C., additional, Morineau, N., additional, Joly, B., additional, Voillat, L., additional, Alexis, M., additional, Fornecker, L. M., additional, Garidi, R., additional, Amorim, S., additional, Bouabdallah, K., additional, Dorvaux, V., additional, Chabrot, C., additional, Feugier, P., additional, Damaj, G., additional, Fleury, J., additional, Delwail, V., additional, Ysebaert, L., additional, Burroni, B., additional, Callanan, M., additional, Legouill, S., additional, and Gressin, R., additional

Published
2023
Full Text
View/download PDF

5. Allogeneic transplantation in T‐cell lymphoma: Lessons from the AATT study

Author

Tournilhac, O., primary, Altmann, B., additional, Friedrichs, B., additional, Bouabdallah, K., additional, Cartron, G., additional, Nickelsen, M., additional, Wulf, G., additional, Leclerc, M., additional, Vilatte, A., additional, Turlure, P., additional, Sanhès, L., additional, Houot, R., additional, Roussel, M., additional, de Leval, L., additional, Rosenwald, A., additional, Gaulard, P., additional, Dreger, P., additional, Glass, B., additional, Latière, C., additional, Damaj, G., additional, Lenz, G., additional, Reimer, P., additional, Banos, A., additional, Bilger, K., additional, Durot, E., additional, Sibon, D., additional, Wagner, E., additional, Nguyen, S., additional, Trümper, L., additional, Ziepert, M., additional, and Schmitz, N., additional

Published
2023
Full Text
View/download PDF

6. Final safety and efficacy results of copanlisib monotherapy in patients with relapsed or refractory iNHL: 6‐year follow‐up of CHRONOS‐1

Author

Dreyling, M., primary, Santoro, A., additional, Mollica, L., additional, Leppä, S., additional, Follows, G. A., additional, Lenz, G., additional, Kim, W. S., additional, Nagler, A., additional, Panayiotidis, P., additional, Demeter, J., additional, Özcan, M., additional, Kosinova, M., additional, Provencio, M., additional, Magagnoli, M., additional, Bouabdallah, K., additional, Heo, D. S., additional, Diong, C. P., additional, Munoz, J., additional, Cao, A., additional, Hiemeyer, F., additional, Odongo, F., additional, Garcia‐Vargas, J., additional, Childs, B. H., additional, and Zinzani, P. L., additional

Published
2023
Full Text
View/download PDF

7. ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY

Author

Zinzani, P. L., primary, Mayer, J., additional, Trotman, J., additional, Bijou, F., additional, de Oliveira, A. C., additional, Song, Y., additional, Zhang, Q., additional, Merli, M., additional, Bouabdallah, K., additional, Ganly, P. S., additional, Zhang, H., additional, Johnson, R., additional, Garcia‐Sancho, A. M., additional, Pulla, M. Provencio, additional, Trněný, M., additional, Yuen, S., additional, Assouline, S. E., additional, Auer, R., additional, Ivanoa, E., additional, Kim, P., additional, Greenbaum, A., additional, Huang, S., additional, Delarue, R., additional, and Flowers, C. R., additional

Published
2023
Full Text
View/download PDF

9. VERY LONG‐TERM FOLLOW‐UP OF RITUXIMAB MAINTENANCE IN YOUNG PATIENTS WITH MANTLE CELL LYMPHOMA INCLUDED IN THE LYMA TRIAL, A LYSA STUDY.

Author

Sarkozy, C., primary, Thieblemont, C., additional, Oberic, L., additional, Moreau, A., additional, Bouabdallah, K., additional, Damaj, G., additional, Gastine, T., additional, Ribrag, V., additional, Casasnovas, O., additional, Haioun, C., additional, Houot, R., additional, Jardin, F., additional, Van Den Neste, E., additional, Cheminant, M., additional, Morschhauser, F., additional, Callana, M., additional, Ghesquieres, H., additional, Gressin, R., additional, Hermine, O., additional, and Le Gouill, S., additional

Published
2023
Full Text
View/download PDF

13. ALK-negative anaplastic large cell lymphoma with DUSP22 rearrangement has distinctive disease characteristics with better progression-free survival: a LYSA study

Author

Sibon, D., Bisig, B., Bonnet, C., Poullot, E., Bachy, E., Cavalieri, D., Fataccioli, V., Bregnard, C., Drieux, F., Bruneau, J., Lemonnier, F., Dupuy, A., Bossard, C., Parrens, M., Bouabdallah, K., Ketterer, N., Berthod, G., Cairoli, A., Damaj, G., Tournilhac, O., Jais, J.P., Gaulard, P., and De Leval, L.

Subjects
Hematology
Abstract

ALK-negative anaplastic large cell lymphoma (ALCL) comprises subgroups harboring rearrangements of DUSP22 (DUSP22- R) or TP63 (TP63-R). Two studies reported 90% and 40% 5-year overall survival (OS) rates in 21 and 12 DUSP22-R/TP63- not rearranged (NR) patients, respectively, making the prognostic impact of DUSP22-R unclear. Here, 104 newly diagnosed ALK-negative ALCL patients (including 37 from first-line clinical trials) from the LYSA TENOMIC database were analyzed by break-apart fluorescence in situ hybridization assays for DUSP22-R and TP63-R. There were 47/104 (45%) DUSP22-R and 2/93 (2%) TP63-R cases, including one DUSP22-R/TP63-R case. DUSP22-R tumors more frequently showed CD3 expression (62% vs. 35%, P=0.01), and less commonly a cytotoxic phenotype (27% vs. 82%; P

Published
2022

14. Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion

Author

Toma, A, Kosmider, O, Chevret, S, Delaunay, J, Stamatoullas, A, Rose, C, Beyne-Rauzy, O, Banos, A, Guerci-Bresler, A, Wickenhauser, S, Caillot, D, Laribi, K, De Renzis, B, Bordessoule, D, Gardin, C, Slama, B, Sanhes, L, Gruson, B, Cony-Makhoul, P, Chouffi, B, Salanoubat, C, Benramdane, R, Legros, L, Wattel, E, Tertian, G, Bouabdallah, K, Guilhot, F, Taksin, A L, Cheze, S, Maloum, K, Nimuboma, S, Soussain, C, Isnard, F, Gyan, E, Petit, R, Lejeune, J, Sardnal, V, Renneville, A, Preudhomme, C, Fontenay, M, Fenaux, P, and Dreyfus, F

Published
2016
Full Text
View/download PDF

15. S205: ZANUBRUTINIB + OBINUTUZUMAB (ZO) VS OBINUTUZUMAB (O) MONOTHERAPY IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PRIMARY ANALYSIS OF THE PHASE 2 RANDOMIZED ROSEWOOD TRIAL

Author

Zinzani, P. L., primary, Mayer, J., additional, Auer, R., additional, Bijou, F., additional, de Oliveira, A. C., additional, Flowers, C. R., additional, Merli, M., additional, Bouabdallah, K., additional, Ganly, P. S., additional, Song, Y., additional, Zhang, H., additional, Johnson, R., additional, García-Sancho, A. M, additional, Provencio, M., additional, Trněný, M., additional, Yuen, S., additional, Tilly, H., additional, Kingsley, E., additional, Tuyman, G., additional, Assouline, S. E., additional, Ivanova, E., additional, Kim, P., additional, Huang, J., additional, Delarue, R., additional, and Trotman, J., additional

Published
2022
Full Text
View/download PDF

16. P1138: COPANLISIB + RITUXIMAB VS RITUXIMAB + PLACEBO IN PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN LYMPHOMA (NHL): UPDATED SAFETY AND EFFICACY FROM THE PHASE III CHRONOS-3 TRIAL

Author

Zinzani, P. L., primary, Özcan, M., additional, Sapunarova, K., additional, Jurczak, W., additional, Hamed, A., additional, Bouabdallah, K., additional, Saydam, G., additional, Geissler, K., additional, Szomor, Á., additional, Lazaroiu, M., additional, Salar, A., additional, Tempescul, A., additional, Nalcaci, M., additional, Gercheva, L., additional, Egyed, M., additional, Panayiotidis, P., additional, Mongay Soler, L., additional, Cao, A., additional, Phelps, C., additional, H Childs, B., additional, and J Matasar, M., additional

Published
2022
Full Text
View/download PDF

17. P1133: SUB-CUTANEOUS RITUXIMAB INDUCTION FOLLOWED BY SHORT RITUXIMAB MAINTENANCE IMPROVES PFS IN PATIENTS WITH LOW-TUMOR BURDEN FOLLICULAR LYMPHOMA. FINAL RESULTS OF FLIRT PHASE III TRIAL, A LYSA STUDY.

Author

Cartron, G., primary, Bachy, E., additional, Tilly, H., additional, Daguindau, N., additional, Pica, G.-M., additional, Bijou, F., additional, Mounier, C., additional, Clavert, A. M., additional, Damaj, G. L., additional, Slama, B., additional, Casasnovas, O., additional, Houot, R., additional, Bouabdallah, K., additional, Sibon, D., additional, Fitoussi, O., additional, Morineau, N., additional, Herbaux, C., additional, Gastinne, T., additional, Fornecker, L.-M., additional, Haioun, C., additional, Launay, V., additional, Araujo, C., additional, Benbrahim, O., additional, Sanhes, L., additional, Gressin, R., additional, Gonzalez, H., additional, Morschhauser, F., additional, Xerri, L., additional, Tarte, K., additional, and Pranger, D., additional

Published
2022
Full Text
View/download PDF

18. P1186: A LARGE FRENCH REAL WORLD MULTICENTRIC PROSPECTIVE COHORT OF PATIENTS WITH LYMPHOMA (REALYSA STUDY): DESCRIPTION OF THE DIFFUSE LARGE B CELL LYMPHOMA PATIENTS IN REAL WORLD IN FRANCE

Author

Ghesquieres, H., primary, Cherblanc, F., additional, Belot, A., additional, Camus, V., additional, Thokagevistk, K., additional, Bouabdallah, K.-K., additional, Esnault, C., additional, Fornecker, L.-M., additional, Micon, S., additional, Bijou, F., additional, Haioun, C., additional, Morineau, N., additional, Ysebaert, L., additional, Damaj, G., additional, Le Gouill, S., additional, Guidez, S., additional, Morschhauser, F., additional, Thiéblemont, C., additional, Chauchet, A., additional, Gressin, R., additional, Jardin, F., additional, Fruchart, C., additional, Labouré, G., additional, Fouillet, L., additional, Lionne-Huyghe, P., additional, Bonnet, A., additional, Lebras, L., additional, Amorim, S., additional, Leyronnas, C., additional, Olivier, G., additional, Guieze, R., additional, Lamy, T., additional, Launay, V., additional, Drenou, B., additional, Fitoussi, O., additional, Detourmignies, L., additional, Abraham, J., additional, Soussain, C., additional, Lachenal, F., additional, Fogarty, P., additional, Cony-Makhoul, P., additional, Bernier, A., additional, Le Guyader-Peyrou, S., additional, Monnereau, A., additional, Boissard, F., additional, and Rossi, C., additional

Published
2022
Full Text
View/download PDF

20. CLONAL ARCHITECTURE OF RELAPSED OR REFRACTORY FOLLICULAR HELPER T‐CELL LYMPHOMA: AN ANCILLARY STUDY OF THE ORACLE TRIAL, A LYSA STUDY.

Author

Loyaux, R., Sako, N., Quang, V. Tran, Bachy, E., Morschhauser, F., Cartron, G., Gressin, R., Daguindau, N., Le Gouill, S., Wolfromm, A., Bouabdallah, K., Ysebaert, L., Casasnovas, O., Robe, C., Delfau, M., Dupuis, J., De Leval, L., Gaulard, P., Sloma, I., and Lemonnier, F.

Subjects
T-cell lymphoma
Abstract

Demonstration of I TET2 i and I DNMT3A i mutations in B cells, myeloid cells, or hematopoietic progenitor cells have suggested that TFHL can emerge from clonal hematopoiesis (CH) in a multi-step process. Follicular helper T-cell lymphoma (TFHL) results from the oncogenic transformation of a TFH cell, driven by mutations in genes involved in epigenetic regulation ( I TET2 i , I DNMT3A, IDH2 i ) and T-cell signaling ( I RHOA i ). Meanwhile, bulk BM cells from 29 patients were sequenced with the same NGS panel and then compared to the mutations found in cfDNA (31 patients) and tumor biopsies (28 patients). [Extracted from the article]

Published
2023
Full Text
View/download PDF

21. Transfusion needs after CD19 CAR T‐cells for large B‐cell lymphoma: predictive factors and impact on outcome. A DESCAR‐T study.

Author

Vic, S., Thibert, J., Bachy, E., Cartron, G., Gastinne, T., Morschhauser, F., Le Bras, F., Bouabdallah, K., Despas, F., Bay, J., Rubio, M., Mohty, M., Casasnovas, O., Choquet, S., Castilla‐Llorente, C., Guidez, S., Loschi, M., Guffroy, B., Carras, S., and La Rochelle, L. Drieu

Subjects
T cells, CD19 antigen, ERYTHROCYTES, LYMPHOMAS, CYTOKINE release syndrome
Abstract

Transfusion needs may impact patients' quality of life and CAR T-cells efficacy through transfusion-related immunomodulation. Transfusion needs after CD19 CAR T-cells for large B-cell lymphoma: predictive factors and impact on outcome. B Introduction: b Patients undergoing CAR T-cell therapy may experience severe cytopenias due to lymphodepleting chemotherapy and/or CAR T-cells. [Extracted from the article]

Published
2023
Full Text
View/download PDF

22. SELINEXOR IN COMBINATION WITH R‐GDP FOR PATIENTS WITH RELAPSED/REFRACTORY B‐CELL LYMPHOMA: PRELIMINARY RESULTS OF THE SELINDA PHASE IB LYSA STUDY ( EUDRACT NUMBER: 2015‐005612‐15)

Author

Maerevoet, M., primary, Casasnovas, O., additional, Cartron, G., additional, Morschhauser, F., additional, Thieblemont, C., additional, Bouabdallah, K., additional, Feugier, P., additional, Szablewski, V., additional, Becker, S., additional, and Tilly, H., additional

Published
2021
Full Text
View/download PDF

23. BRENTUXIMAB VEDOTIN AS CONSOLIDATION TREATMENT IN PATIENTS WITH STAGE I/II CLASSICAL HODGKIN'S LYMPHOMA AND A POSITIVE FDG‐PET AFTER 2 CYCLES OF ABVD: A LYSA PHASE 2 STUDY

Author

Gastinne, T., primary, Bouabdallah, K., additional, Moatti, H., additional, Tessoulin, B., additional, Shiano del colella, J. M., additional, Lamy, T., additional, Casasnovas, O., additional, Borel, C., additional, Stamatoullas, A., additional, Gac, A. C., additional, Chaoui, D., additional, Feugier, P., additional, Delmer, A., additional, Bonnet, C., additional, Fornecker, Luc‐M., additional, Lazarovici, J., additional, Bras, F., additional, Ghesquieres, H., additional, Meignan, M., additional, Traverse Glehen, A., additional, and Brice, P., additional

Published
2021
Full Text
View/download PDF

24. IMPACT OF DUSP22 REARRANGEMENT ON THE PROGNOSIS OF SYSTEMIC ALK‐NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA: A LYSA AND TENOMIC STUDY

Author

Sibon, D, primary, Bisig, B, additional, Bonnet, C, additional, Bachy, E, additional, Cavalieri, D, additional, Fataccioli, V, additional, Drieux, F, additional, Bruneau, J, additional, Lemonnier, F, additional, Bossard, C, additional, Bouabdallah, K, additional, Parrens, M, additional, Damaj, G, additional, Tournilhac, O, additional, Jais, J. P, additional, Gaulard, P, additional, and de Leval, L, additional

Published
2021
Full Text
View/download PDF

25. GENDER DISPARITIES IN QUALITY OF LIFE OF FRENCH PATIENTS ONE YEAR AFTER THE DIAGNOSIS OF LYMPHOMA. A LYSA STUDY

Author

Paunescu, A.‐C., primary, Paget, J., additional, Bergman, C. Copie, additional, Malak, S., additional, Le Gouill, S., additional, Ribrag, V., additional, Bouabdallah, K., additional, Sibon, D., additional, Rumpold, G., additional, Preau, M., additional, Mounier, N., additional, Haioun, C., additional, Jardin, F., additional, and Besson, C., additional

Published
2021
Full Text
View/download PDF

26. CHRONOS‐3: RANDOMIZED PHASE III STUDY OF COPANLISIB PLUS RITUXIMAB VS RITUXIMAB/PLACEBO IN RELAPSED INDOLENT NON‐HODGKIN LYMPHOMA (INHL)

Author

Zinzani, P. L., primary, Capra, M., additional, Özcan, M., additional, Lv, F., additional, Li, W., additional, Yañez, E., additional, Sapunarova, K., additional, Lin, T., additional, Jin, J., additional, Jurczak, W., additional, Hamed, A., additional, Wang, M.‐C., additional, Baker, R., additional, Bondarenko, I., additional, Zhang, Q., additional, Feng, J., additional, Geissler, K., additional, Lazaroiu, M., additional, Saydam, G., additional, Szomor, Á., additional, Bouabdallah, K., additional, Galiulin, R., additional, Uchida, T., additional, Mongay Soler, L., additional, Cao, A., additional, Hiemeyer, F., additional, Mehra, A., additional, Childs, B. H., additional, Shi, Y., additional, and Matasar, M. J., additional

Published
2021
Full Text
View/download PDF

27. Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study

Author

Dreyling, M. Santoro, A. Mollica, L. Leppä, S. Follows, G. Lenz, G. Kim, W.S. Nagler, A. Dimou, M. Demeter, J. Özcan, M. Kosinova, M. Bouabdallah, K. Morschhauser, F. Stevens, D.A. Trevarthen, D. Munoz, J. Rodrigues, L. Hiemeyer, F. Miriyala, A. Garcia-Vargas, J. Childs, B.H. Zinzani, P.L.

Abstract

Safety profiles of oral PI3K inhibitors have resulted in US FDA black box warnings regarding fatal/serious toxicities. The approved intravenous PI3K inhibitor copanlisib has low incidence of severe toxicities and no black box warnings, but chronic treatment effects were unknown. We provide an update on safety and efficacy of copanlisib with a minimum 2-year follow-up of the CHRONOS-1 study. A total of 142 patients with histologically confirmed indolent B-cell lymphoma who had relapsed after or were refractory to ≥2 prior treatments received intravenous copanlisib 60 mg on days 1, 8, and 15 (28-day cycle). The primary efficacy endpoint was objective response rate (ORR) after ≥4 cycles (independent assessment). The predominant histology was follicular lymphoma (n = 104). The ORR was 60.6% (seven additional complete responses since primary analysis). Secondary endpoints of median duration of response, progression-free survival, and overall survival were 14.1 months (median follow-up, 16.1 months), 12.5 months (median follow-up, 14.0 months), and 42.6 months (median follow-up, 31.5 months), respectively. Median safety follow-up was 6.7 months; 26% of patients received treatment for >1 year. Common treatment-emergent adverse events (TEAEs) (all grade/grade 3/grade 4) were transient hyperglycemia (50.0%/33.1%/7.0%), diarrhea (35.2%/8.5%/0%), transient hypertension (29.6%/23.9%/0%), and neutropenia (28.9%/9.2%/14.8%). Serious AEs were largely unchanged, with no new cases of pneumonitis (4.2%), diarrhea (2.8%), or grade 5 events. Note, TEAEs showed no evidence for increased incidence or worsening following longer exposure in patients treated >1 year. Long-term follow-up of patients with relapsed/refractory indolent B-cell lymphoma treated with intravenous copanlisib demonstrated durable, enhanced responses without evidence of worsening TEAEs, as reported for orally administered PI3K inhibitors. © 2019 The Authors. American Journal of Hematology published by Wiley Periodicals, Inc.

Published
2020

28. Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma

Author

Manson, G., primary, Brice, P., additional, Herbaux, C., additional, Silva, M. G., additional, Bouabdallah, K., additional, Deau, B., additional, Bouteloup, J., additional, Schiano, J. M., additional, Nicolas-Virelizier, E., additional, Maerevoet, M., additional, Ghesquieres, H., additional, Stamatoullas, A., additional, Antier, C., additional, Carlo-Stella, C., additional, de Charette, M., additional, Poizeau, F., additional, Dercle, L., additional, and Houot, Roch, additional

Published
2020
Full Text
View/download PDF

29. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

Author

Morschhauser F, Fowler N, Feugier P, Bouabdallah R, Tilly H, Palomba M, Fruchart C, Libby E, Casasnovas R, Flinn I, Haioun C, Maisonneuve H, Ysebaert L, Bartlett N, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica G, Garcia-Sancho A, Lopez-Guillermo A, Larouche J, Ando K, da Silva M, Andre M, Zachee P, Sehn L, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, Salles G, and RELEVANCE Trial Investigators

Published
2018

30. FIRST-LINE THERAPY OF T-CELL LYMPHOMA: ALLOGENEIC OR AUTOLOGOUS TRANSPLANTATION FOR CONSOLIDATION - FINAL RESULTS OF THE AATT STUDY

Author

Tournilhac, O., primary, Truemper, L., additional, Ziepert, M., additional, Bouabdallah, K., additional, Nickelsen, M., additional, Maury, S., additional, Reimer, P., additional, Jaccard, A., additional, Herr, W., additional, Wilhelm, M., additional, Cartron, G., additional, Wulf, G., additional, Sanhes, L., additional, Dreger, P., additional, Lamy, T., additional, Kroschinsky, F., additional, Lindemann, H., additional, Roussel, M., additional, Viardot, A., additional, Sibon, D., additional, Delmer, A., additional, De Leval, L., additional, Damaj, G.L., additional, Gisselbrecht, C., additional, Gaulard, P., additional, Rosenwald, A., additional, Friedrichs, B., additional, Altmann, B., additional, and Schmitz, N., additional

Published
2019
Full Text
View/download PDF

31. OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS. RESULTS OF LYMA‐101 TRIAL, A LYSA GROUP STUDY

Author

Le Gouill, S., primary, Beldi‐Ferchiou, A., additional, Cacheux, V., additional, Salles, G., additional, Canioni, D., additional, Bodet‐Milin, C., additional, Alcantara, M., additional, Delwail, V., additional, Gastinne, T., additional, Thieblemont, C., additional, Maisonneuve, H., additional, Lamy de la Chapelle, T., additional, Oberic, l., additional, Bouabdallah, K., additional, Ribrag, V., additional, Delfau‐Larue, M., additional, Macintyre, E., additional, and Hermine, O., additional

Published
2019
Full Text
View/download PDF

32. OUTCOME OF PATIENTS WITH C-MYC REARRANGED DIFFUSE LARGE B CELL LYMPHOMA ASSOCIATED OR NOT WITH BCL2 AND/OR BCL6 REARRANGEMENT: A MULTICENTRIC AND RETROSPECTIVE STUDY

Author

Favre, S., primary, Botella-Garcia, C., additional, Bijou, F., additional, Deau-Fisher, B., additional, Banos, A., additional, Rispal, P., additional, Saint-Lézer, A., additional, Fitoussi, O., additional, Lifermann, F., additional, Labouré, G., additional, Dagada, C., additional, Milpied, N., additional, and Bouabdallah, K., additional

Published
2019
Full Text
View/download PDF

33. FIRST APPLICATION OF MINIMAL RESIDUAL DISEASE ANALYSIS IN SPLENIC MARGINAL ZONE LYMPHOMA TRIALS: PRELIMINARY RESULTS FROM BRISMA/IELSG36 PHASE II STUDY

Author

Ferrero, S., primary, Ladetto, M., additional, Beldjord, K., additional, Drandi, D., additional, Stelitano, C., additional, Bernard, S., additional, Castagnari, B., additional, Bouabdallah, K., additional, Cesaretti, M., additional, Alvarez, I., additional, Gressin, R., additional, Ponzoni, M., additional, Tripodo, C., additional, Traverse-Glehen, A., additional, Baseggio, L., additional, Liberati, A., additional, Merli, M., additional, Tessoulin, B., additional, Patti, C., additional, Cabras, M., additional, Feugier, P., additional, Pozzi, S., additional, Zucca, E., additional, Iannitto, E., additional, and Thieblemont, C., additional

Published
2019
Full Text
View/download PDF

35. Copanlisib monotherapy activity in relapsed or refractory indolent B-cell lymphoma: Combined analysis from phase I and II studies

Author

Zinzani, P.L., primary, Santoro, A., additional, Mollica, L., additional, Follows, G.A., additional, Bouabdallah, K., additional, Morschhauser, F., additional, Patnaik, A., additional, Huang, L., additional, Hiemeyer, F., additional, Benson, A., additional, Genvresse, I., additional, Garcia-Vargas, J.E., additional, Childs, B.H., additional, and Dreyling, M.H., additional

Published
2018
Full Text
View/download PDF

36. Phosphatidylinositol 3-kinase inhibition by Copanlisib in relapsed or refractory indolent lymphoma

Author

Dreyling, M. Santoro, A. Mollica, L. Leppä, S. Follows, G.A. Lenz, G. Kim, W.S. Nagler, A. Panayiotidis, P. Demeter, J. Öcan, M. Kosinova, M. Bouabdallah, K. Morschhauser, F. Stevens, D.A. Trevarthen, D. Giurescu, M. Cupit, L. Liu, L. Köchert, K. Seidel, H. Peña, C. Yin, S. Hiemeyer, F. Garcia-Vargas, J. Childs, B.H. Zinzani, P.L.

Abstract

Purpose: Phosphatidylinositol 3-kinase (PI3K) signaling is critical for the proliferation and survival of malignant B cells. Copanlisib, a pan-class I PI3K inhibitor with predominant activity against PI3K-a and -d isoforms, has demonstrated efficacy and a manageable safety profile in patients with indolent lymphoma. Patients and Methods: In this phase II study, 142 patients with relapsed or refractory indolent lymphoma after two or more lines of therapy were enrolled to receive copanlisib 60 mg intravenously on days 1, 8, and 15 of a 28-day cycle. The primary end point was objective response rate; secondary end points included duration of response, progression-free survival, and overall survival. In addition, safety and gene expression were evaluated. Results: Median age was 63 years (range, 25 to 82 years), and patients had received a median of three (range, two to nine) prior regimens. The objective response rate was 59% (84 of 142 patients); 12% of patients achieved a complete response. Median time to response was 53 days. Median duration of response was 22.6 months, median progression-free survival was 11.2 months, and median overall survival had not yet been reached. The most frequent treatment-emergent adverse events were transient hyperglycemia (all grades, 50%; grade 3 or 4, 41%) and transient hypertension (all grades, 30%; grade 3, 24%). Other grade $3 events included decreased neutrophil count (24%) and lung infection (15%). High response rates to copanlisib were associated with high expression of PI3K/B-cell receptor signaling pathway genes. Conclusion: PI3K-α and -δ inhibition by copanlisib demonstrated significant efficacy and a manageable safety profile in heavily pretreated patients with relapsed or refractory indolent lymphoma. © 2017 by American Society of Clinical Oncology.

Published
2017

37. REALMA: Subset of patients with Marginal Zone Lymphomas from the French nationwide REALYSA real‐world prospective cohort.

Author

Bommier, C., Donzel, M., Rossi, C., Fornecker, L., Bijou, F., Chauchet, A., Lebras, L., Ysebaert, L., Haioun, C., Bouabdallah, K., Morineau, N., Gastinne, T., Amorim, S., Jardin, F., Abraham, J., Lamy de la Chapelle, T., Gressin, R., Fouillet, L., Fruchart, C., and Morschhauser, F.

Subjects
LYMPHOMAS, NON-Hodgkin's lymphoma
Abstract

Regarding the B initial workup b , while at least one imagery was offered in 97% of patients, SP 18 sp FDG-PET/CT (EMZL 78%, SMZL 62%, NMZL 78%) was performed more frequently than CT-scan at baseline (EMZL 73%, SMZL 62%, NMZL 71%), although 47% patients underwent both procedures. Diagnosis of MZL was mostly evoked by general practitioners (48%) but patients were finally treated by hematologists (98%). B Background: b Marginal Zone Lymphomas (MZL) are a heterogeneous group of lymphomas that include three subtypes: extranodal MZL (EMZL), splenic MZL (SMZL) and nodal MZL (NMZL). [Extracted from the article]

Published
2023
Full Text
View/download PDF

38. Cell‐free DNA sequencing allows the identification of the mutational profile of TFH lymphomas and has a predictive value: a LYSA study.

Author

Sako, N., Delfau, M., Bachy, E., Morschhauser, F., Cartron, G., Casasnovas, O., Gressin, R., Daguindau, N., Tournilhac, O., Bouabdallah, K., Le Gouill, S., Andre, M., Robe, C., Dupuis, J., De Leval, L., Gaulard, P., and Lemonnier, F.

Subjects
CELL-free DNA, DNA sequencing, CIRCULATING tumor DNA, LYMPHOMAS
Abstract

Only one patient had detectable I TET2 i , I DNMT3A i , I IDH2 i , and I RHOA i mutations in the cfDNA and not in the tumor biopsy, corresponding to a tumor with low neoplastic cell content. By contrast, 3 patients had I DNMT3A i mutations, not affecting the R882 residue, detected in the cfDNA but not in the tumor likely corresponding to clonal hematopoiesis not related to the TFHL. Common I TET2 i mutations were detected in the tumor of 36/43 (84%) and in cfDNA of 33/43 (77%) patients, with a median variant allele frequency (VAF) of 17.75% vs. 9.8% respectively. [Extracted from the article]

Published
2023
Full Text
View/download PDF

40. Copanlisib treatment in patients with relapsed or refractory indolent B-cell lymphoma: Subgroup analyses from the CHRONOS-1 study

Author

Provencio Pulla, M., primary, Santoro, A., additional, Mollica, L., additional, Leppä, S., additional, Follows, G., additional, Lenz, G., additional, Kim, W.S., additional, Nagler, A., additional, Panayiotidis, P., additional, Demeter, J., additional, Özcan, M., additional, Kosinova, M., additional, Bouabdallah, K., additional, Morschhauser, F., additional, Ishida, T., additional, Huang, L., additional, Garcia-Vargas, J., additional, Childs, B.H., additional, Zinzani, P.L., additional, and Dreyling, M., additional

Published
2017
Full Text
View/download PDF

41. COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT B-CELL LYMPHOMA (CHRONOS-1)

Author

Dreyling, M., primary, Santoro, A., additional, Mollica, L., additional, Leppä, S., additional, Follows, G.A., additional, Lenz, G., additional, Kim, W., additional, Nagler, A., additional, Panayiotidis, P., additional, Demeter, J., additional, Özcan, M., additional, Kosinova, M., additional, Bouabdallah, K., additional, Morschhauser, F., additional, Stevens, D.A., additional, Trevarthen, D., additional, Giurescu, M., additional, Liu, L., additional, Koechert, K., additional, Peña, C., additional, Cupit, L., additional, Yin, S., additional, Hiemeyer, F., additional, Garcia-Vargas, J., additional, Childs, B.H., additional, and Zinzani, P., additional

Published
2017
Full Text
View/download PDF

43. Rituximab maintenance after autologous stem-cell transplantation in patients with mantle cell lymphoma, final result of the LyMA trial conducted on behalf the LYSA group

Author

Le Gouill, S., primary, Thieblemont, C., additional, Oberic, L., additional, Moreau, A., additional, Bouabdallah, K., additional, Dartigeas, C., additional, Damaj, G., additional, Gastinne, T., additional, Ribrag, V., additional, Feugier, P., additional, Casasnovas, O., additional, Zerazhi, H., additional, Haioun, C., additional, Maisonneuve, H., additional, Van Den Neste, E., additional, Tournilhac, O., additional, Le Dû, K., additional, Morschhauser, F., additional, Cartron, G., additional, Fornecker, L., additional, Salles, G., additional, Tilly, H., additional, Lamy, T., additional, Gressin, R., additional, and Hermine, O., additional

Published
2017
Full Text
View/download PDF

44. Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B‐cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE‐170 phase 2 trial

Author

Zinzani, P., primary, Thieblemont, C., additional, Melnichenko, V., additional, Osmanov, D., additional, Bouabdallah, K., additional, Walewski, J., additional, Majlis, A., additional, Fogliatto, L., additional, Caballero Barrigón, M.D., additional, Christian, B., additional, Gulbas, Z., additional, Özcan, M., additional, Salles, G.A., additional, Shipp, M.A., additional, Balakumaran, A., additional, Chlosta, S., additional, Chatterjee, A., additional, and Armand, P., additional

Published
2017
Full Text
View/download PDF

46. Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSA

Author

Houot, R., primary, Soussain, C., additional, Tilly, H., additional, Haioun, C., additional, Thieblemont, C., additional, Casasnovas, O., additional, Bouabdallah, K., additional, Morschhauser, F., additional, Le Gouill, S., additional, Salles, G.A., additional, Hoang-Xuan, K., additional, Choquet, S., additional, Marchand, T., additional, Laurent, C., additional, Pangault, C., additional, and Lamy, T., additional

Published
2016
Full Text
View/download PDF

47. Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion

Author

Toma, A, primary, Kosmider, O, additional, Chevret, S, additional, Delaunay, J, additional, Stamatoullas, A, additional, Rose, C, additional, Beyne-Rauzy, O, additional, Banos, A, additional, Guerci-Bresler, A, additional, Wickenhauser, S, additional, Caillot, D, additional, Laribi, K, additional, De Renzis, B, additional, Bordessoule, D, additional, Gardin, C, additional, Slama, B, additional, Sanhes, L, additional, Gruson, B, additional, Cony-Makhoul, P, additional, Chouffi, B, additional, Salanoubat, C, additional, Benramdane, R, additional, Legros, L, additional, Wattel, E, additional, Tertian, G, additional, Bouabdallah, K, additional, Guilhot, F, additional, Taksin, A L, additional, Cheze, S, additional, Maloum, K, additional, Nimuboma, S, additional, Soussain, C, additional, Isnard, F, additional, Gyan, E, additional, Petit, R, additional, Lejeune, J, additional, Sardnal, V, additional, Renneville, A, additional, Preudhomme, C, additional, Fontenay, M, additional, Fenaux, P, additional, and Dreyfus, F, additional

Published
2015
Full Text
View/download PDF

48. Combination of pixantrone with rituximab, ifosfamide and etoposide in relapsed/refractory aggressive non‐Hodgkin lymphoma. Results from a phase II LYSA study (PIVeR).

Author

Fornecker, L., Delwail, V., Thieblemont, C., Ghesquieres, H., Bouabdallah, K., Tilly, H., Le Calloch, R., Morschhauser, F., Costello, R., Slama, B., Gyan, E., Chauchet, A., Ngirabacu, M., Durot, E., Choquet, S., Capdupuy, C., Le Goff, M., Voillat, L., Snauwaert, S., and Amorim, S.

Subjects
NON-Hodgkin's lymphoma, IFOSFAMIDE, RITUXIMAB, DIFFUSE large B-cell lymphomas
Abstract

R/R disease was defined as follows: (1) autologous stem-cell transplantation (ASCT) eligible patients who failed to achieve a CR after at least one salvage therapy, (2) patients in first relapse after ASCT or (3) patients not eligible for ASCT who failed to achieve a CR after at least one prior treatment. Results from a phase II LYSA study (PIVeR) B Introduction: b The prognosis of patients with relapsed/refractory aggressive non-hodgkin lymphoma (R/R aNHL) remains poor with conventional immunochemotherapies. [Extracted from the article]

Published
2023
Full Text
View/download PDF

50. 499 Phase 2a study of copanlisib, a novel phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with relapsed/refractory, indolent or aggressive lymphoma

Author

Dreyling, M., primary, Zinzani, P.L., additional, Bouabdallah, K., additional, Bron, D., additional, Cunningham, D., additional, Linton, K., additional, Thieblemont, C., additional, van den Neste, E., additional, Vitolo, U., additional, Grunert, J., additional, Giurescu, M., additional, Mappa, S., additional, Childs, B.H., additional, and Morschhauser, F., additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results